Adding tafasitamab to treatment with lenalidomide and rituximab improved progression-free survival in patients with relapsed or refractory follicular lymphoma.
Annual Meeting, held on 7-10 December, early results from the double-blind, randomised, placebo-controlled, Phase III inMIND clinical trial were presented.
Adding the humanized CD19-targeted monoclonal antibody tafasitamab (Monjuvi) to a backbone of lenalidomide (Revlimid) and ...
Treatment with tafasitamab for relapsed/refractory DLBCL in the United States was supported by data from a retrospective analysis.
Incyte (INCY) announced additional results from the pivotal Phase 3 inMIND trial evaluating treatment with tafasitamab, a humanized Fc-modified ...
The global Minimal Residual Disease market is expected to grow to USD 2.55 Billion by 2029, up from USD 1.43 Billion in 2024, ...
Ounce of Hope, a leading aquaponic cannabis brand, is redefining industry standards by pairing sustainable, aquaponic ...
With a median follow-up of 14.1 months, adding tafasitamab to lenalidomide and rituximab reduced the risk of progression, ...
Elizabeth A. Brem, MD, an assistant clinical professor in the Division of Hematology/Oncology, School of Medicine at the University of California, Irvine, discusses multiple types of therapies used in ...
Incyte’s (INCY) tafasitamab-cxix was granted FDA orphan designation as a treatment of nodal marginal zone lymphoma, according to a post to the ...
DelveInsight's 'Follicular Lymphoma Pipeline Insight 2024' report provides comprehensive global coverage of pipeline ...